Xin-Min Guo*,
Jia-Lin Chen,
Bao-Hui Zeng,
Ji-Chuang Lai,
Cui-Yan Lin and
Mei-Yan Lai
Department of Ultrasound, Guangzhou Red Cross Hospital, Medical College, Jinan University, 396 Tongfu Middle Road, Guangzhou, Guangdong 510220, P. R. China. E-mail: Guoxm1509257@163.com
First published on 27th October 2020
Nanobubbles (NBs) are considered to be a new generation of ultrasound-responsive nanocarriers that can effectively target tumors, accurately release multi-drugs at desired locations, as well as simultaneously perform diagnosis and treatment. In this study, we designed theranostic NBs (FTY720@SPION/PFP/RGD-NBs) composed of RGD-modified liposomes as the shell, and perflenapent (PFP), superparamagnetic iron oxide nanoparticles (SPION), and fingolimod (2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, FTY720) encapsulated as the core. The prepared FTY720@SPION/PFP/RGD-NBs were black spheres with a diameter range of 160–220 nm, eligible for enhanced permeability and retention (EPR) effects. The calculated average drug loading efficiency (LE) and encapsulation efficiency (EE) of the FTY720@SPION/PFP/RGD-NBs were 9.18 ± 0.61% and 88.26 ± 2.31%, respectively. With the promotion of low-intensity focused ultrasound (LIFU), the amount and the rate of FTY720 released from the prepared NB complex were enhanced when compared to the samples without LIFU treatment. In vitro magnetic resonance imaging (MRI) trials showed that the prepared FTY720@SPION/PFP/RGD-NBs had a high relaxation rate and MRI T2-weighted imaging (T2WI) scanning sensitivity conditions. The cell viability studies demonstrated that both HepG2 and Huh7 cells co-cultured with FTY720@SPION/PFP/RGD-NB (100 μg mL−1) + LIFU treatment had the lowest survival rate compared with the other groups at 24 h and 48 h, showing that FTY720@SPION/PFP/RGD-NB had the strongest anti-tumor efficiency among the prepared NBs. The cytotoxicity study also demonstrated that the prepared NBs had low toxicity to normal fibroblast 3T3 cells. Cellular uptake studies further indicated that both LIFU treatment and RGD modification could effectively improve the tumor-targeted effects, thereby enhancing the antitumor efficacy. The qRT-PCR results indicated that LIFU-mediated FTY720@SPION/PFP/RGD-NB could significantly cause the activation of Caspase3, Caspase9 and p53 compared to the control group, inducing HepG2 apoptosis. These results together indicated that FTY720@SPION/PFP/RGD-NBs combined with LIFU may serve as a multifunctional drug delivery platform for hepatocellular carcinoma treatment and provide a new strategy for tumor visualization by MRI.
Ultrasound-targeted microbubble destruction (UTMD) technology has received increasing attention in cancer treatment applications.6–10 Microbubbles (MBs, 1–4 μM) are spherical shells made of various materials that encapsulate gas (e.g. perflenapent, PFP) used as ultrasonic contrast agents, playing a vital role in the ultrasound diagnosis of many diseases.11,12 Recent studies have shown that the UTMD carrier can target the drug and gene to local tumor tissues, and then destroy the microbubble structure to release the drug under specific ultrasonic irradiation.9,13–15 UTMD can cause a series of changes in the cell structure and function of target tissues, increase pores on the cell surface, enhance permeability of tissues and cells, and improve phagocytic capacity of cells, thereby promoting the targeted delivery and therapeutic efficacy of the agents into cells.16–19 However, the size of MBs limits their mobility to penetrate the tumor blood vessel wall (the gap between 380 nm and 780 nm). Therefore, nanobubbles (NBs) are considered to be a new generation of ultrasound-responsive nanocarriers that can improve the drug delivery performance both in vitro and in vivo. NBs can move from the blood vessels and enter the surrounding tissues, thereby improving the efficiency of delivery and local localization.20–22 Similar to MBs, NBs can also be used as cavitation nuclei, causing sound pore effects through UTMD, resulting in instantaneous pore formation of biofilms and changing cell permeability. Liufu et al. prepared the NBs sensitive to acoustic response and glutathione (GSH), using polyethylene glycol-disulfide bond-polyethylenimine (PSP).23 Their study showed that the UTMD technology combined with the NBs effectively promoted the deliver efficacy of ALDH1 shRNA, promoting apoptosis of ovarian cancer stem cells.23 Sun and colleagues designed sinoporphyrin sodium (DVDMS, sonosensitizer and photosensitizer)-loaded iRGD-modified liposomes that are used for glioma therapy.8 Through UTMD, the prepared liposomes (round 110–130 nm) could penetrate the blood–brain barrier (BBB), enhance the accumulation of DVDMS in the glioma tissue, increase reactive oxygen species (ROS) generation, and show strong antitumor efficacy both in vitro and in vivo.8
The use of micro- or nano-ultrasonic contrast agents in combination with other contrast agents can achieve multi-modal imaging, which has become a future trend in the diagnosis and treatment of various diseases. Although ultrasound is a real-time, non-invasive imaging mode, its resolution on soft tissues is worse than magnetic resonance imaging (MRI). Feshitan et al. synthesized the Gd(III)-bound MBs, which could be used to measure the cavitation events during MRI-guided focused ultrasound therapy and tracked the biodistribution of shell residues.24 Li et al. developed Fe3O4-embedded MBs as the contrast agent for both ultrasonography and MRI, and their results indicated that the shell structure plays a key role in influencing the imaging quality.25 Yang et al. utilized PLA and PVA double-layered shells to prepare the MBs (3.98 μm) loading with superparamagnetic iron oxide nanoparticles (SPIONs, 12 nm), which showed a great potential to serve as double contrast agents in the applications of ultrasonography and MRI.26 Their study demonstrated that the prepared SPIONs/MBs could be manipulated instantaneously and locally in vivo via cavitation by ultrasound irradiation, and the dynamic MR susceptibilities imaging technique was used to monitor these in vivo contrast changes.26
Fingolimod (2-amino-2[2-(4-octylphenyl)ethyl]-1,3-propanediol, FTY720) is a new type of immunosuppressive agent suppressing the homing of lymphocytes, which has been used in the clinical treatment of immune rejection after organ transplantation. FTY720 can be phosphorylated in vivo and become an analogue of sphingosine-1-phosphate (S1P), which competitively binds to S1P receptor 1 on the surface of cell membranes, inhibiting the role of S1P.27,28 A number of studies have further demonstrated that non-phosphorylated FTY720 can inhibit the SK1 signaling pathway, as well as interfered with multiple intracellular oncogenic signaling pathways related to cancer development, resulting in strong anti-tumor and anti-metastatic effects against different types of cancers such as HCC, leukemia, breast cancer, prostate cancer, and bladder cancer.29–34 However, the administration of FTY 720 at high doses might cause serious cardiovascular effects by its interaction with S1P receptors.35,36 A well-designed NB drug delivery platform equipped with tumor-targeting agents (e.g. ligands or peptides) can effectively load and transport therapeutic drugs to the lesion areas, providing new strategies to solve the problem. Combined with the UTMD technology, the customized drug delivery platforms can greatly enhance the accumulation of drugs in the tumor tissues rather than in the normal cells, reducing the side effects and toxicity of the drugs.6,8,21,22
In this study, we designed theranostic NBs (FTY720@SPION/PFP/RGD-NBs) composed of RGD-modified liposomes as the shell, and PFP, SPION, and FTY720 encapsulated as the core. The physiochemical properties of the prepared multifunctional drug carrier at nanoscale were characterized. The drug release and imaging effect in vitro under low-intensity focused ultrasound (LIFU) conditions were studied. The in vitro cytotoxicity, cellular uptake and cancer-related gene expression levels of various prepared NBs were investigated against HCC cells. The proposed multifunctional FTY720@SPION/PFP/RGD-NBs showed the following features: (I) effective HCC active-targeting with the assistance of LIFU; (II) enhanced EPR effects due to the nanoscale of NBs, when compared with MBs; and (III) noninvasive and real-time imaging diagnosis using MRI.
HCC cells (HepG2 and Huh7 cells) and fibroblast NIH 3T3 cells were obtained from the Chinese Academy of Sciences (CAS, Shanghai, China). The cells were cultured in DMEM supplemented with 10% FBS and 100 U mL−1 penicillin–streptomycin at 37 °C in a humidified incubator with 5% CO2.
The drug-loaded liposomes FTY720@SPION/PFP/NBs were synthesized by a thin-film hydration method. Briefly, DPPC (30 mg), DSPE-PEG-MAL (15 mg) and FTY720 (10 mg) were dissolved in tetrahydrofuran (10 mL) and added into a round-bottom flask. After the powders were completely dissolved, SPIONs (25 mg mL−1 @ 100 μL) were added and stirred at room temperature for 1 h, then the solvent was evaporated at 40 °C for 2 h using a rotary evaporator under vacuum. Phosphate buffered saline (5 mL, pH7.4) was added to the flask, and the flask was sonicated to obtain a brown suspension. The suspension was transferred into a 20 mL epoxide tube, and PFF (200 μL) was then slowly added. An ultrasonic pulverizer (200 W, 4s–4s) was used to emulsify the suspension in the EP tube for 20 min under ice bath. The obtained product was dialyzed (MWCO = 3500) with distilled water for 3 days and then stored at −4 °C to obtain FTY720@SPION/PFP/NBs.
The target drug-loaded liposomes FTY720@SPION/PFP/RGD-NBs were prepared as follows. FTY720@PFP/Fe3O4/lipid NPs (10 mg mL−1 @ 10 mL), EDC (50 mg) and NHS (25 mg) were mixed under stirring at 37 °C for 30 min. The RGD peptide was then added into the solution and stirred magnetically at 4 °C for 8 hours. The obtained product was dialyzed (MWCO = 3500) with distilled water for 3 days and then stored at −4 °C to obtain FTY720@SPION/PFP/RGD-NBs.
The structure of SPIONs was characterized using an X-ray diffractometer (XRD) (D/Max-2550, Rigaku Inc., Japan). The magnetization properties of the prepared SPIONs and FTY720@SPION/PFP/RGD-NBs were analyzed using a vibrating sample magnetometer (VSM7407, Lake Shore Cryotronics, Inc., USA). The morphological properties of SPIONs and NB complex were examined using a transmission electron microscope (TEM) (H-800, Hitachi, Japan). The size and zeta potential of FTY720@SPION/PFP/RGD-NBs were detected by dynamic light scattering (DLS) using a Nano Zetasizer (Malvern Instruments Ltd., UK).
To measure the encapsulation efficiency (EE) and loading efficiency (LE) of the FTY720 in the FTY720@SPION/PFP/RGD-NBs, a certain amount of FTY720@SPION/PFP/RGD-NBs were subjected to centrifugation (12000g, 15 min). The supernatant was collected for absorbance measurement using a UV-Vis spectrophotometer at a wavelength of 220 nm. The concentration of FTY720 was determined with a standard curve according to the Beer–Lambert law. The LE and EE were calculated using eqn (1) and (2).
![]() | (1) |
![]() | (2) |
To measure the stabilities of FTY720@SPION/PFP/RGD-NBs, the prepared NB complex was dispersed into a PBS solution, and then divided into 2 groups, which were stored at 4 °C and 20 °C, respectively. The size distribution and PDI of NBs under both conditions were measured every day for 7 days.
![]() | (3) |
MRI (1.5T scanner, Philips, Best, Netherlands) was also used to monitor the cellular uptake efficiency of the prepared NBs in vitro. Briefly, HepG2 cells (1 × 104 cells per well) were cultured in 96-well plates at 37 °C. After 24 h, the culture media were removed and the cells were treated with fresh media containing FTY720@SPION/PFP/NBs or FTY720@SPION/PFP/RGD-NBs. Two of the four groups were subjected to LIFU treatment for 60 s (power of 2.4 W cm−2, a duty cycle of 50% and a pulse frequency of 100 Hz). All the samples were incubated at 37 °C for 1 h. Then, the cells were washed three times with PBS, centrifuged, and resuspended in PBS containing 0.5% agarose in 96-well plates for the MRI test.
Genes | Primer | Sequence |
---|---|---|
Caspase-9 | Forward | 5′-GCAGTAACCCCGAGCCAGATG-3′ |
Reverse | 5′-CCGGAGGAAATTAAAGCAACCAG-3′ | |
Caspase-3 | Forward | 5′-TGCAGCAAACCTCAGGGAAA-3′ |
Reverse | 5′-TCACCATGGCTCAGAAGCAC-3′ | |
p53 | Forward | 5′-GTGACACGCTTCCCTGGATT-3′ |
Reverse | 5′-GAGCTTCATCTGGACCTGGG-3′ |
NBs | Zeta potential (mV) | EE (%) | LE (%) |
---|---|---|---|
FTY720@SPION/PFP/RGD-NBs | −38.00 ± 0.41 | 88.26 ± 2.31 | 9.18 ± 0.61% |
SPIONs are contrast agents for T2-weighted imaging in MRI, which have good biocompatibility and biodegradability. They can bind to hemoglobin and involve in the metabolic processes, avoiding accumulation in the body. Compared with other contrast agents, SPIONs have stronger MRI contrast enhancement effects, higher detection sensitivities, a large number of surface binding sites, and the ability to construct composite nanostructures for multi-mode imaging.26,39–41 In this study, SPIONs were prepared by a high-temperature pyrolysis method37,38 and then encapsulated within NBs to achieve real-time MRI visualization.
The structure of SPIONs was confirmed by the XRD spectrum (Fig. S1†). The TEM image showed that the prepared SPIONs were spherical and monodisperse, with an average particle diameter of 8 nm and a PDI of 0.202 ± 0.012 (Fig. S2†). Magnetic response is one of the important performance indicators for testing magnetic materials, and hysteresis loops are used to characterize the responsiveness of magnetic materials to external magnetic fields. The profiles of hysteresis loops (Fig. 2) showed that the saturation magnetization (Ms) of SPIONs and FTY720@SPION/PFP/RGD-NBs was 59.9 emu g−1 and 19.95 emu g−1, respectively. The hysteresis curves of all the samples passed through the origin, suggesting that the remanence was zero. This result indicated that the prepared SPIONs and NB complex were both superparamagnetic. Though the saturation magnetization of FTY720@SPION/PFP/RGD-NBs was lower than that of SPIONs, it showed good magnetic responsiveness to external magnetic fields and can be used for subsequent MRI studies.
The MRI T2WI scan results are shown in Fig. 2B. The images of first line were the water control group, and the images of second line were the prepared FTY720@SPION/PFP/RGD-NBs. As the concentration of SPIONs increased, the MRI image gradually darkened. This result suggested that the SPIONs in the prepared NBs complex could effectively reduce the T2 relaxation time and enhance the MRI effects. In Fig. 2C, the transverse relaxation time T2 of samples of different concentrations was obtained according to the scanned MRI T2 map. The reciprocal was plotted against the Fe concentration (mM) in the sample and linearly fitted to calculate the transverse relaxation rate of the sample R2 (114.56 mM−1 s−1). This result confirmed that the prepared FTY720@SPION/PFP/RGD-NBs had a high relaxation rate and T2WI scanning sensitivity conditions.
UTMD technology is a novel targeted drug or gene delivery method due to its non-invasive, safe, effective, and controllable characteristics. In this study, we used low-intensity focused ultrasound (LIFU) as the ultrasound trigger to burst the drug-loaded NBs, thereby improving the targeted deposition of the drug in the tumor tissues and reducing the toxic effects towards normal tissues. The in vitro release profiles of FTY720 from FTY720@SPION/PFP/RGD-NB with the promotion of LIFU were evaluated at pH 7.4 at 37 °C (Fig. 3). The amount of FTY720 released from the prepared NB complex was increased with the increase in the LIFU intensity. The corresponding drug release amount at 72 hours was 38.4 ± 1.1%, 58.7 ± 2.1%, 68.4 ± 3.0%, and 93.5 ± 2.9%, when the LIFU intensity was set to 0, 0.8, 1.6 and 2.4 W cm−2 respectively with an exposure time of 1 min. In addition, the samples with LIFU treatment showed a much faster release rate of FTY720 than the NBs without ultrasound exposure. At 12 h, FTY720 released by the sample treated with LIFU at 2.4 W cm−2, 1.6 W cm−2 and 0.8 W cm−2 were 78.1 ± 2.4%, 56.4 ± 3.0% and 43.6 ± 2.4%, respectively. The amount of FTY720 released from the prepared NBs without the LIFU promotion was only 25.7 ± 1.4%. These results indicated that the selected LIFU intensity (2.4 W cm−2 with exposure time of 1 min) had the ability to burst the prepared NB complex and caused rapid drug release at the target site, which provided a basis for subsequent tumor treatment experiments.
To investigate HCC cell killing effect of FTY720@SPION/PFP/RGD-NBs with the combination of LIFU, we measured the viability of HepG2 and Huh7 cells treated with various NB complexes at different concentrations with or without ultrasound irradiation (Fig. 4a–d). For different concentrations of SPION/PFP/RGD-NBs, both HepG2 and Huh7 cell proliferations at 24 h and 48 h were all above 80%, indicating that the prepared NB drug carrier has low toxicity to the cells. For the other FTY720-loaded NBs, the cytotoxicity showed a dosage-dependent manner. The higher the concentration of the drug-loaded NBs, the lower the cell viability. After ultrasound treatment, the HepG2 cells co-cultured with FTY720@SPION/PFP/RGD-NB (100 μg mL−1) showed the lowest survival rate when compared to the other groups, which was only 15.21% and 14.71% at 24 h and 48 h, respectively. The Huh7 cells co-cultured with the FTY720@SPION/PFP/RGD-NB (100 μg mL−1) showed similar trends (Fig. 4c and d), and the samples of FTY720@SPION/PFP/RGD-NB + LIFU (100 μg mL−1) showed the lowest survival rate (35.21% and 28.18% at 24 h and 48 h, respectively) compared to the other groups. For both HepG2 and Huh7 cells treated with FTY720@SPION/PFP/NB + LIFU (i.e. non-RGD-targeted NBs + LIFU), the cell viability was lower than that for cells treated with FTY720@SPION/PFP/NB and FTY720@SPION/PFP/RGD-NB (i.e. RGD-targeted NBs) at 24 h. This might be due to the fact that the LIFU resulted in rapid drug (FTY720) release from the NBs within 24 h (as shown in Fig. 3), which would cause enhanced anti-tumor effects. Other studies in the literature also demonstrated with the ultrasound irritation could mediate the rapid drug release from liposomes and instantaneously change the permeability of cell membranes, leading to effective drug absorptions by tumor cells.42,43
To further investigate the cytotoxicity of the prepared NBs on normal cell lines, we performed CCK8 assay using normal fibroblast 3T3 cells co-cultured with the prepared NBs (Fig. 4e and f). The cell viability of 3T3 cells at both 24 h and 48 h were over 80% when NBs were equal or below 50 μg mL−1; when NBs were set at a higher concentration of 100 μg mL−1, the cell viability of 3T3 cells treated with FTY720@SPION/PFP/NB + LIFU or FTY720@SPION/PFP/RGD-NB + LIFU at 24 h decreased slightly to 78.14% and 76.27%, respectively; and the cell viability of these two samples at 48 h were 79.88% and 77.98%, respectively. The cell viability of 3T3 cells treated with other NBs at 100 μg mL−1 was all above 80%. These results suggested that the prepared NBs had good biocompatibility to health cell lines and had a higher targeting efficiency for HCC cells than normal fibroblast cells.
Effective intercellular uptake of drug-loaded NBs can enhance the therapeutic effects on cancer cells. By co-culturing with HepG2 cells in vitro, the targeting efficiency of the prepared drug-loaded NBs with or without ultrasound exposure (power 2.4 W cm−2, 60 s) was evaluated using CLSM. As shown in Fig. 5, the cell nuclei were stained and indicated in blue, while the prepared NBs were indicated in red. For the cells with FTY720@SPION/PFP/NB (i.e. non-RGD-targeted group), there were very weak red fluorescence signals gathered around the cell membranes, while for the cells with FTY720@SPION/PFP/RGD-NB (i.e. RGD-targeted group), red fluorescence was clearly visible around the cell membranes. Combined with ultrasound exposure, both these two groups (i.e. FTY720@SPION/PFP/NB + LIFU and FTY720@SPION/PFP/RGD-NB + LIFU) showed enhanced red fluorescence signals around the cells, and the red signals for the RGD-targeted NBs + LIFU group were stronger than that of the non-RGD-targeted NBs + LIFU group. This might be due to the fact that the ultrasound irritation could cause cavitation effects and temporarily open the cell membranes. At the same time, the drug-loaded NBs were burst due to ultrasound irritation, and the drug could be effectively released from the collapsed NBs and accumulated in the tumor cells. Furthermore, the RGD peptide has been proved to have a high bind affinity to ανβ3 integrin, which was normally associated with various tumor cells.44 A number of studies demonstrated that the RGD modified nano-drug delivery systems could improve the active targeting efficiency of tumor cells.45–48 Thereby, the ultrasound irritation could mediate the drug-loaded NBs to be more easily internalized into the cells, and the prepared RGD-modified NBs could further improve cellular uptake and increase the delivery efficiency of FTY720.
![]() | ||
Fig. 5 Targeting efficiency of the prepared RGD-NBs with or without LIFU treatment: HepG2 cells were co-cultured with cy5.5-labelled FTY720@SPION/PFP/NBs or FTY720@SPION/PFP/RGD-NBs for 1 h. |
The cellular uptake efficiency of the FTY720@SPION/PFP/NB or FTY720@SPION/PFP/RGD-NB was also evaluated by observing MRI T2-weighted imaging (T2WI) and by measuring T2 value of HepG2 cells when incubated with different nanoparticles using a clinical 1.5T MRI scanner. As shown in Fig. 6, the T2 value of the control group a (i.e. water) was highest, followed by the cells co-cultured with FTY720@SPION/PFP/NBs and FTY720@SPION/PFP/RGD-NBs without LIFU treatments (groups b and d). The T2 values of the cells subjected to the LIFU treatment, i.e. group c (FTY720@SPION/PFP/NB + LIFU) and group e (FTY720@SPION/PFP/RGD-NB + LIFU), both showed a remarkable decrease compared to the control group a, and the T2 value of group e (FTY720@SPION/PFP/RGD-NB + LIFU) was the lowest among all samples. These results indicated that with the assistance of LIFU treatment, the prepared NBs, i.e. FTY720@SPION/PFP/NBs and FTY720@SPION/PFP/RGD-NBs could be more effectively burst in the tumor area and showed an enhanced negative contrast in the corresponding MRI images. Group e showed about 0.67 times T2 value of that of group c, suggesting that the RGD-equipped NBs might increase the cell absorption of the prepared NBs under the same conditions. This finding was consistent with the results of cellular targeting efficiency of the prepared RGD-NBs using CLSM (Fig. 5).
The mRNA expression levels of Caspase-3, Caspase-9 and p53 related to the apoptosis were detected by qRT-PCR assay. The results indicated that all the prepared NBs with or without LIFU treatment could increase the mRNA expression levels of Caspase-9, Caspase-3 and p53 when compared with the control group (Fig. 7). The sample with the highest mRNA expression levels was FTY720@SPION/PFP/RGD-NB + LIFU group. Tumors cells can increase the expression of anti-apoptotic genes, down-regulate the expression of apoptosis genes, and block the cell death pathway at different levels of the apoptotic signal cascade reactions, thereby evading apoptosis to ensure survival of cancer cells. Apoptosis mainly goes through two pathways: death receptor pathway (exogenous pathway) and mitochondrial pathway (endogenous pathway).49 The activation of either pathway will cause the protease to hydrolyze and activate the caspase family. Caspase-3 and Caspase-9 are the key molecules in the caspase family to execute and initiate cell apoptosis, playing vital roles in the process of cell apoptosis. p53 is one of the famous tumor suppressors in cells, and its expression can be enhanced by cytotoxic stress, resulting in cell cycle arrest and apoptosis. In this study, the expression levels of apoptosis-related mRNA Caspase-9, Caspase-3 and p53 were up-regulated in the HepG2 cells treated with various NBs. It is speculated that the prepared NBs could promote apoptosis of HepG2 cells. Combined with LIFU, the expression levels of these mRNA were higher than those without LIFU treatment, indicating that LIFU mediation might enhance these gene expressions.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: 10.1039/d0ra06415g |
This journal is © The Royal Society of Chemistry 2020 |